MARKET

ANVS

ANVS

ANNOVIS BIO, INC.
AMEX

Real-time Quotes | Nasdaq Last Sale

26.14
-1.31
-4.77%
Closed 16:00 05/18 EDT
OPEN
26.98
PREV CLOSE
27.45
HIGH
27.42
LOW
25.65
VOLUME
87.29K
TURNOVER
--
52 WEEK HIGH
47.99
52 WEEK LOW
3.830
MARKET CAP
181.60M
P/E (TTM)
-21.9185
1D
5D
1M
3M
1Y
5Y
Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research
Dr. Fang has authored 15 published papers including two on axonal transport and several on protein aggregation Berwyn, Pennsylvania--(Newsfile Corp. - May 18, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing...
Newsfile · 10h ago
Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome
Berwyn, Pennsylvania--(Newsfile Corp. - May 13, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it ha...
Newsfile · 5d ago
Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that ...
Newsfile · 05/11 10:51
Annovis Bio to Ring Closing Bell at the New York Stock Exchange
Berwyn, Pennsylvania--(Newsfile Corp. - May 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, is pleased to announc...
Newsfile · 05/10 18:00
Kuntz Lesher Capital LLC Buys Vanguard Mega Cap Value ETF, iShares National Muni Bond ETF, ...
GuruFocus News · 05/10 05:42
10-Q: ANNOVIS BIO, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Cautionary Note Regarding...
Edgar Online - (EDG = 10Q, 10K) · 05/06 17:01
Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
Berwyn, Pennsylvania--(Newsfile Corp. - May 6, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the U....
Newsfile · 05/06 11:45
Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
Collaborative mice study with UC San Diego to study brain development from embryo to old age Berwyn, Pennsylvania--(Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's dis...
Newsfile · 04/29 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANVS. Analyze the recent business situations of ANNOVIS BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANVS stock price target is 32.50 with a high estimate of 45.00 and a low estimate of 20.00.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/Director/Primary Contact
Michael Hoffman
Executive Director
Maria Maccecchini
Director
Claudine Bruck
Director
Robert Whelan
Director
Mark White
Independent Director
Reid McCarthy
No Data
About ANVS
Annovis Bio, Inc. is a clinical stage, drug platform company. The Company is focused on addressing neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is engaged in developing drugs that normalize the transport of information within and between nerve cells, called axonal transport. Its lead product pipelines are ANVS-401, which include ANVS-401 for AD, ANVS-401 for AD-DS, ANVS-401 for PD; ANVS-405 and ANVS-301. Its ANVS-401 restores axonal transport and homeostasis in the brain by inhibiting the synthesis of neurotoxic proteins. The Company is in an ongoing Phase II A proof-of-concept study in mild to moderate AD patients and a ready program to conduct a second Phase II A study in PD patients. The Company has also developed compound to treat acute neurodegeneration traumatic brain injury (TBI) and stroke.

Webull offers kinds of Annovis Bio Inc stock information, including AMEX:ANVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANVS stock methods without spending real money on the virtual paper trading platform.